INTRODUCTION
============

Hiccup is a repetitive, involuntary, spasmodic and characteristic voice that can occur with closure of the glottis suddenly as a result of involuntary contraction of the diaphragm and respiratory muscles.[@b1-cpn-15-410] Though the pathophysiological processes that lead to hiccups have not been completely established, central nervous system disorders, gastrointestinal disorders and tumors, metabolic and electrolyte disorders and various drugs are implicated as causes of hiccup.[@b1-cpn-15-410] In drug-induced hiccups, aripiprazole is very often incriminated for transient and persistent hiccups among adult and adolescent patients.[@b2-cpn-15-410],[@b3-cpn-15-410] Here, we present a case of hiccups arising in adolescent with an extensive metabolizer genotype for CYP2D6 when using aripiprazole in addition to extended-release methylphenidate. Of note, his hiccups ceased when aripiprazole was used without methylphenidate.

CASE
====

The patient was a 16-year-old boy who was referred to the outpatient clinic with complaints of behavioral problems like difficulty in anger control, running away from school and home, smoking and telling lies. In his medical history, he was diagnosed with the attention deficit and hyperactivity disorder (ADHD) 5 years ago by a child and adolescent psychiatrist and received methylphenidate 54 mg/day alone, with significant benefit for 5 years. But, within the last year, he started to fight, tell lies, smoke and also to be a school truant. Finally, it was learned that he took his father's car without permission and had an accident with it. His family told that he did not have attention deficit problems during methylphenidate treatment and his academic achievement was satisfactory. In addition, he did not want to use methylphenidate anymore. In the psychiatric evaluation, he did not have eye contact and he told that he did not want to talk. He seemed very nervous. And after ten minutes in silence, he shut the door hard and went out.

According to psychiatric assessment, he was diagnosed with ADHD and conduct disorder (CD) according to Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM 5)[@b4-cpn-15-410] and was prescribed aripiprazole 2.5 mg/day adding to extended-release methylphenidate at a dose of 54 mg/day. Next day, he had an episode of hiccups in the morning starting 12 hours after the administration of first dose of 2.5 mg/day aripiprazole at night and hiccups lasted for 4 hours, which led him to come to clinic in great concern. He was extremely disturbed from this side effect. Therefore, we were unable to convince the patient to use another drug for behavioral problems. Owing to this side effect, it was thought that he may be a poor or intermediate metabolizer and pharmacogenetic testing was requested from medical genetics laboratory for CYP2D6.

While waiting for test results, behavioral problems of the case were aggravated and his mother gave aripiprazole again at the dose of 2.5 mg/day for 2 weekend days saying that it was a vitamin for his lack of appetite, due to methylphenidate because he had drug holidays for methylphenidate every weekend. She told that she observed no hiccup with only aripiprazole but when she gave it again in weekdays in combination with methylphenidate, the hiccup started 12 hours later again and lasted for an hour at this time. She thought that he was better with aripiprazole when administered at alone, so at present patient is on only aripiprazole 5 mg/day as the schools are closed, and no hiccup is observed. Moreover, his behavioral problems decreased markedly. Meanwhile, our case was genotyped as extensive/normal metabolizer for CYP2D6. Evaluation with the Naranjo algorithm revealed a score of 7 (probably adverse drug reaction).[@b5-cpn-15-410]

DISCUSSION
==========

Here, we present a case of hiccups arising in a CYP2D6 extensive/normal metabolizer adolescent who was using aripiprazole plus extended-release methylphenidate for the treatment of ADHD and CD. The use of atypical antipsychotics concomitantly with stimulants in children and adolescents is becoming more common as clinicians try to treat comorbidities involving ADHD, CD, oppositional defiant disorder, mental retardation and pediatric bipolar disorder despite their potentially opposing pharmacological mechanism.[@b6-cpn-15-410],[@b7-cpn-15-410]

Previous reports of hiccups with aripiprazole exist in the literature,[@b2-cpn-15-410],[@b3-cpn-15-410] but our case is of interest in that a drug used commonly in child psychiatry such as methylphenidate promoted aripiprazole to cause hiccup. Although the precise roles of neurotransmitters within the reflex arc of hiccups remain to be completely understood, current data suggest that both dopamine and serotonin may play roles in the development of hiccups. Methylphenidate is currently the most commonly prescribed agent used to treat ADHD and it is thought to exert its effects by inhibiting dopamine and norepinephrine reuptake and by binding the serotonin transporter.[@b8-cpn-15-410],[@b9-cpn-15-410] It is also used for the treatment of hiccup in patients.[@b10-cpn-15-410],[@b11-cpn-15-410]

Furthermore, aripiprazole, which is a partial agonist of dopamine 2,3 and 5-HT1A receptors, is used to stabilize dopamine and serotonin systems. Previous reports stated that both hypo- and hyper-dopaminergic states may give rise to hiccups and both drugs can lead to these conditions in our case.[@b2-cpn-15-410],[@b3-cpn-15-410]

The members of the cytochrome P450 protein family mediate the metabolism of many pharmaceutical agents and genetic variability in these enzymes may dictate a patient's response to a drug. Identification of genotypes of these enzymes can minimize adverse drug reactions and improve patients' response. CYP2D6 is the main cytochrome P450 enzyme involved in the metabolism of antipsychotics and antidepressants.[@b12-cpn-15-410] In our case, we utilized PGX-CYP2D6 Strip Assay (Vienna Lab Diagnostics, Vienna, Austria) to determine the genotype of CYP2D6. This test diagnoses patients as extensive/normal (two copies of wild-type alleles), poor (one wild-type allele plus one variant allele with reduced enzyme activity or two variant alleles with reduced enzyme activity) and ultra-rapid metabolizer (multiple copies of wild-type alleles).[@b13-cpn-15-410]

The patient was genotyped as extensive (normal) metabolizer. As a result, elimination of aripiprazole involves two cytochrome P450 enzymes (CYP2D6, CYP3A4) and methylphenidate, which is both a substrate and a weak inhibitor of CYP2D6 at the same time, can lead to increased aripiprazole blood levels by blocking the metabolism of aripiprazole or by competing with aripiprazole for CYP2D6 metabolism. Thus, aripiprazole can cause hiccup as seen in our case.

In conclusion, it is recommended that clinicians should take drug interactions into consideration when using more than one drug concurrently. Profiling cytochrome P450 isoenzymes genotypes should be conducted in all patients prior to the onset of treatment when more than one drug is used in the same patient in order to benefit from treatment in the short term and to prevent side effects and drug interactions.
